Refer-A-Friend Program
Sneeze, Wheeze and Itch Associates, LLC
Great News: Positive Top-Line Result for Safety and Efficacy of a Non-Steroidal Topical Treatment for Atopic Dermatitis in Children (MASA SWIA)
On July 11, 2023, MASA’s research team at Sneeze Wheeze and Itch Associates received great news regarding the positive top-line research results on the safety and efficacy of a non-steroidal topical treatment for Atopic Dermatitis (AD) in children. The SWIA research team, led by Dr. Siri as Principal Investigator, contributed to the pivotal Phase 3 study for ruxolitinib cream, along with 98 other research centers worldwide!
Incyte, a pharmaceutical company, has released positive results from a study evaluating a cream called ruxolitinib (Opzelura®) for the treatment of atopic dermatitis (AD) in children. AD is a chronic skin condition that affects about 13% of children in the U.S. The study showed that more patients treated with ruxolitinib cream achieved successful treatment compared to those treated with a non-medicated cream. The cream was well-tolerated, and no new safety concerns were observed. Incyte plans to discuss these positive results with regulatory agencies to determine the next steps.
Atopic dermatitis (AD), the most common type of eczema, affects millions of people in the U.S., particularly children. It is characterized by inflamed and itchy skin, which can cause discomfort and infections. The recently completed study, called TRuE-AD3, enrolled over 300 children aged 2 to 12 years who had been diagnosed with AD for at least three months. The primary goal of the study was to assess the proportion of patients achieving successful treatment based on specific criteria. The study results will be presented at a scientific meeting.
Opzelura cream is a formulation of ruxolitinib, a medication that targets specific pathways in the body associated with inflammation. It has already been approved for the treatment of vitiligo and atopic dermatitis in the U.S. Opzelura offers a potential non-steroidal topical therapy for children with AD, which could provide relief from symptoms and improve their quality of life. Incyte holds the worldwide rights for the development and commercialization of ruxolitinib cream.
Read about the clinical trial here: https://classic.clinicaltrials.gov/ct2/show/NCT04921969
Read more about the announcement here: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-topline-results-phase-3-trial
Follow Sneeze, Wheeze and Itch Associates on Facebook: https://www.facebook.com/SWIA.Clinical.Research
Refer-A-Friend Program
REFER A QUALIFYING FRIEND,
AND YOU COULD RECEIVE UP TO $25!
How It Works
To refer a friend or family member for a clinical trial at SWIA and earn up to $25, simply:
1. Print and fill out a Refer-A-Friend coupon (click here to download).
2. Your friend or family member must contact SWIA about the research study and present this coupon at their first study visit.
3. If your friend or family member qualifies to screen for the study and enrolls (randomizes and receives study medication, study treatment or placebo), the referrer (YOU) will earn $25!
Please Remember
-You can refer as many people as you want and there is no limit to how much money you can make!
-To be eligible, the friend or family member that you refer must be new to our database, and YOU must be in our database as well. To be added to our database, call 309-452-0995 and ask to speak to a research coordinator.
-The decision to participate in a study is up to your friend or family member.
-Refer-A-Friend payments are made AFTER your friend or family member has completed the randomization visit.
-For questions about the Refer-A-Friend program or to inquire about the status of a referral, please call 309-452-0995.
For more information regarding current studies, please call 309-452-0995 and ask to speak to a coordinator.